Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.79 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.66 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.63 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.63 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.63 |
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | MITF | O75030 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14093238 | 0.92 | HRH3 (0.78) | KDM4EHRH3USP2ALDH1A1HPGD | |
| SCHEMBL270794 | 0.89 | KDM4E (1.00) | KDM4EHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL17300729 | 0.89 | KDM4E (0.94) | KDM4EHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL20234324 | 0.88 | KDM4E (0.75) | KDM4EHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL17694433 | 0.87 | KDM4E (0.97) | KDM4EHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL12780029 | 0.87 | KDM4E (0.97) | KDM4EHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL14349553 | 0.85 | KDM4E (0.71) | KDM4EHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL14349567 | 0.84 | KDM4E (0.75) | KDM4EHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL4404318 | 0.84 | KDM4E (0.75) | KDM4EHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL13761571 | 0.84 | KDM4E (0.75) | KDM4EHRH3PSMB1PSMB5PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045484-B2 | Inhibitors of the BMP signaling pathway | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20140011805-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2014-01-09 | — | — | US | disclosed |
| US-8507501-B2 | Inhibitors of the BMP signaling pathway | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| WO-2013024282-A2 | COMPOUNDS AND THEIR USES | DOMAINEX LIMITED (GB) | 2013-02-21 | — | — | WO | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-7417053-B2 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312209-B2 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | KDM4E 1877/4885HRH3 2212/4885PSMB1 2616/4885 |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | KDM4E 2789/4885HRH3 485/4885PSMB1 2286/4885 |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | BMP1, BMP2K, BMP2 | KDM4E 1806/4885HRH3 2326/4885PSMB1 2880/4885 |
| US-20140011805-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | BMP1, BMP2K, BMP2 | KDM4E 1806/4885HRH3 2326/4885PSMB1 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.